Abstract
Although recent trial results of anti-CD3 therapy are promising, there have been conflicting results of various immunotherapeutic agents used in patients with type 1 diabetes. We conducted a systematic review and meta-analysis to determine the efficacy of nonantigen-based immunotherapeutic approaches for preservation of beta-cell function in patients with type 1 diabetes. We searched MEDLINE, EMBASE, Cochrane CENTRAL, reference lists, and content expert files up to September 2006. Eligible studies were randomized controlled trials (RCTs) of antiproliferative agents (methotrexate, azathioprine), monoclonal antibodies (CD3, CD4), T-cell inhibitors (cyclosporin) and other immunotherapeutic agents (photopheresis, linomide, fusidin, buffy coat, intravenous immunoglobulin, BCG, nicotinamide) in patients with newly diagnosed type 1 diabetes followed for > or = 6 months. Pairs of reviewers working independently and with adequate reliability assessed the trials' methodological quality, collected data, and conducted random-effects meta-analyses on measures of preservation of beta-cell function (e.g. C-peptide secretion, insulin independence). Of the 299 potentially relevant articles identified after an initial search, 20 trials met selec...Continue Reading
References
Apr 1, 1992·Journal of Diabetes and Its Complications·J S Skyler, A Rabinovitch
Nov 1, 1991·Statistics in Medicine·A Whitehead, J Whitehead
Oct 1, 1990·Journal of Autoimmunity·F PantŏA Galluzzo
Jun 1, 1989·Diabetes·J J CookJ M Court
Jul 19, 1986·Lancet·G FeutrenA Lallemand
Sep 8, 1988·The New England Journal of Medicine·J SilversteinS Johnson
Mar 1, 1988·Diabetes Care·D O'BrienO Pontesilli
Oct 1, 1987·Diabetes·J CavanaughJ Barbosa
May 22, 1986·The New England Journal of Medicine·G S Eisenbarth
May 1, 1986·Diabetologia·A K FoulisR S Weir
Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Jan 1, 1994·Diabetic Medicine : a Journal of the British Diabetic Association·P PozzilliL Lucentini
Jun 10, 1998·Annals of Internal Medicine
Oct 1, 1998·Diabetologia·R CoutantP F Bougnères
Oct 17, 1998·Diabetes Care·J F ElliottR M Couch
Dec 29, 1998·Diabetologia·G R BrownB Beutler
Mar 31, 1999·Diabetes Care·H H ParvingJ Nerup
Oct 20, 1999·Diabetes Care·H F AllenH P Chase
Jul 20, 2000·Clinical Immunology : the Official Journal of the Clinical Immunology Society·B A Buckingham, C I Sandborg
Jul 24, 2001·Archives of Disease in Childhood·J LudvigssonG Berlin
May 31, 2002·The New England Journal of Medicine·UNKNOWN Diabetes Prevention Trial--Type 1 Diabetes Study Group
Jan 25, 2003·BMJ : British Medical Journal·Douglas G Altman, J Martin Bland
Apr 30, 2003·Diabetes·Carla J GreenbaumUNKNOWN Immunology of Diabetes Society
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Dec 25, 2003·Diabetes·Jerry P PalmerMichael W Steffes
Mar 27, 2004·Lancet·E A M GaleUNKNOWN European Nicotinamide Diabetes Intervention Trial (ENDIT) Group
Apr 28, 2005·Diabetes Care·Jay S SkylerEllen Leschek
May 28, 2005·Diabetes·Kevan C HeroldJeffrey A Bluestone
Jun 24, 2005·The New England Journal of Medicine·Bart KeymeulenLucienne Chatenoud
Jul 5, 2005·Diabetologia·I CongetF Nicoletti
Nov 9, 2005·The Journal of Experimental Medicine·Matthias G von Herrath, Gerald T Nepom
Nov 11, 2005·American Journal of Therapeutics·Theresa AlyGeorge S Eisenbarth
Jan 21, 2006·Chest·Gordon GuyattHolger Schünemann
Mar 14, 2007·Clinical and Experimental Immunology·T Staeva-VieiraM von Herrath
Citations
Aug 19, 2011·Indian Journal of Endocrinology and Metabolism·Vishvas Garg
Sep 15, 2011·Expert Opinion on Biological Therapy·Shannon A Miller, Erin St Onge
Jun 23, 2012·Diabetes·Govindarajan RajagopalanChella S David
Jul 31, 2016·Endocrine·Chrysoula RizavaApostolos Tsapas
Jun 2, 2011·Nature Reviews. Drug Discovery·Frank Waldron-Lynch, Kevan C Herold
Aug 6, 2013·Transplantation·Jan RingersJohan W de Fijter